Evommune, Inc. (EVMN) Securities Fraud Investigation – Levi & Korsinsky
Evommune stock dropped approximately 38% after EVO756 missed its Phase 2b primary endpoint in chronic spontaneous urticaria, erasing millions in shareholder value in a single session. NEW YORK, July 7, 2026 /PRNewswire/ — Evommune, Inc. (NYSE: EVMN) shareholders lost approximately 38% of… Source: prnewswire Country: United States